Methods of using .alpha.-phosphonosulfonate squalene synthetase
申请人:Bristol-Myers Squibb Company
公开号:US05470845A1
公开(公告)日:1995-11-28
.alpha.-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is H, alkyl, arylalkyl or aryl; R.sup.4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.
1,1-Bisphosphonate Squalene Synthase Inhibitors: Interplay Between the Isoprenoid Subunit and the Diphosphate Surrogate
作者:David R. Magnin、John K. Dickson、Janette V. Logan、R. Michael Lawrence、Ying Chen、Richard B. Sulsky、Carl P. Ciosek、Scott A. Biller、Thomas W. Harrity、Kern G. Jolibois、Lori K. Kunselman、Lois C. Rich、Dorothy A. Slusarchyk
DOI:10.1021/jm00014a012
日期:1995.7
Inhibitors of squalenesynthase have the potential to be superior cholesterol-lowering agents. We previously disclosed that lipophilic 1,1-bisphosphonates I are potent squalenesynthaseinhibitors and orallyactive cholesterol-lowering agents in animal models (Ciosek, C. P., Jr.; et al. J. Biol. Chem. 1993, 268, 24832-24837). In this paper, we describe modifications to the bisphosphonate moiety, in
Isoprenoid phosphinylformic acid squalene synthetase inhibitors and method for preparing the same
申请人:E.R. SQUIBB & SONS, INC.
公开号:EP0418814A2
公开(公告)日:1991-03-27
Compounds which are inhibitors of cholesterol biosynthesis (by inhibiting de novo squalene biosynthesis), and thus are useful as hypocholesterolemic agents and antiatherosclerotic agents, are provided which have the structure
wherein R2 is a metal ion, lower alkyl or H;
R3 is a metal ion or lower alkyl;
R is R1-(CH2)n-, R1-(CH2)m-O- or R1-(CH2)m-OCH2-, wherein n is 1 to 4 and m is 0 to 3, and
R1 is R5-Q1-Q2-03- wherein R5, Q1, Q2 and Q3 are as defined herein.
New intermediates, new methods of preparation and a method for using such compounds to inhibit cholesterol biosynthesis are also provided.
Compounds which are inhibitors of cholesterol biosynthesis (by inhibiting de novo squalene biosynthesis), and thus are useful as hypocholesterolemic agents and antiatherosclerotic agents are provided which have the structure
and analogs thereof, wherein R¹, R², R³ and R⁴ are the same or different and are H, lower alkyl, a metal ion or a prodrug ester;
R⁵ is H, halogen or lower alkyl;
Zq is substituted alkenyl, substituted alkynyl, mixed alkenyl-alkynyl or substituted phenylalkyl, or substituted biphenylalkyl, alkylphenylalkyl or alkyl, including all stereoisomers thereof.
New methods for using such compounds to inhibit cholesterol biosynthesis are also provided.
Use of phosphonomethylphosphinate squalene synthetase inhibitors for the manufacture of a medicament for the lowering cholesterol
申请人:E.R. SQUIBB & SONS, INC.
公开号:EP0514124A2
公开(公告)日:1992-11-19
A method is provided for inhibiting cholesterol biosynthesis by inhibiting de novo squalene production employing methylene phosphonoalkylphosphinate compounds.